We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$2.19B
Turnover
34.18%
1-Year Est. Return
374.99%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.12%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.42% |
| 2 | Miscellaneous | 9.68% |
| 3 | Financials | 1.51% |
| 4 | Technology | 0.08% |
| 5 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Abivax
ABVX
$8.06B
| $155M | 9.14% |
1,394,019
+76,690
| +6% | +$9.08M |
2024 Q1
8 quarters
|
|
2
Protagonist Therapeutics
PTGX
$8.84B
| $105M | 6.17% |
994,119
-55,049
| -5% | -$4.87M |
2023 Q4
9 quarters
|
|
3
Roivant Sciences
ROIV
$24.6B
| $91M | 5.36% |
3,285,906
-143,056
| -4% | -$3.67M |
2023 Q4
9 quarters
|
|
4
Immunovant
IMVT
$5.68B
| $66.5M | 3.92% |
2,679,010
+198,042
| +8% | +$5.13M |
2023 Q4
9 quarters
|
|
5
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $49.4M | 2.91% |
75,940
+21,256
| +39% | +$14.5M |
2025 Q2
3 quarters
|
|
6
DELISTED
Terns Pharmaceuticals
TERN
| $48.2M | 2.84% |
914,699
+373,084
| +69% | +$15.3M |
2025 Q2
3 quarters
|
|
7
Cytokinetics
CYTK
$8.89B
| $41.7M | 2.45% |
632,556
+92,390
| +17% | +$5.87M |
2023 Q4
9 quarters
|
|
|
8
DELISTED
Crinetics Pharmaceuticals
CRNX
| $41.4M | 2.44% |
1,139,331
+829,963
| +268% | +$37.1M |
2024 Q2
7 quarters
|
|
9
Alpha Architect 1-3 Month Box ETF
BOXX
$14.4B
| $39.2M | 2.31% |
337,125
| – | – |
2024 Q1
8 quarters
|
|
|
10
Denali Therapeutics
DNLI
$2.93B
| $35.9M | 2.12% |
1,871,455
+1,819,339
| +3,491% | +$36.2M |
2024 Q1
8 quarters
|
|
|
11
Beam Therapeutics
BEAM
$2.55B
| $34.5M | 2.03% |
+1,446,375
| New | +$40.1M |
2026 Q1
0 quarters
|
|
12
Zai Lab
ZLAB
$2.64B
| $26.8M | 1.58% |
1,425,367
+178,847
| +14% | +$3.31M |
2023 Q4
9 quarters
|
|
13
Septerna Inc
SEPN
$1.75B
| $26.2M | 1.54% |
1,089,818
-67,793
| -6% | -$1.78M |
2025 Q1
4 quarters
|
|
|
14
Vir Biotechnology
VIR
$1.77B
| $24.6M | 1.45% |
+2,744,714
| New | +$21.9M |
2026 Q1
0 quarters
|
|
15
DBV Technologies S.A. American Depositary Shares
DBVT
$573M
| $21.2M | 1.25% |
+1,012,866
| New | +$21.2M |
2026 Q1
0 quarters
|
|
16
Anteris Technologies
AVR
$620M
| $21M | 1.24% |
3,789,132
+2,550,355
| +206% | +$14.7M |
2024 Q4
5 quarters
|
|
|
17
Inspire Medical Systems
INSP
$2.03B
| $20.9M | 1.23% |
405,197
+390,197
| +2,601% | +$27.3M |
2025 Q3
2 quarters
|
|
18
Scholar Rock
SRRK
$4.95B
| $20M | 1.18% |
407,273
+337,684
| +485% | +$15.1M |
2024 Q2
7 quarters
|
|
19
Rhythm Pharmaceuticals
RYTM
$6.06B
| $18.4M | 1.08% |
211,450
+160,101
| +312% | +$15.6M |
2024 Q4
5 quarters
|
|
20
Spyre Therapeutics
SYRE
$7.49B
| $17.1M | 1% |
338,323
+304,272
| +894% | +$11.5M |
2025 Q1
4 quarters
|
|
21
CytomX Therapeutics
CTMX
$525M
| $16M | 0.94% |
3,410,190
-772,579
| -18% | -$3.92M |
2024 Q1
8 quarters
|
|
22
Prothena Corp
PRTA
$436M
| $15.4M | 0.9% |
1,581,443
+123,679
| +8% | +$1.13M |
2025 Q2
3 quarters
|
|
23
Sanofi
SNY
$96.5B
| $15.3M | 0.9% |
316,939
+253,465
| +399% | +$11.8M |
2025 Q2
3 quarters
|
|
24
Vaxcyte
PCVX
$10.3B
| $15.1M | 0.89% |
259,137
-56,505
| -18% | -$3.07M |
2025 Q1
4 quarters
|
|
25
Monopar Therapeutics
MNPR
$482M
| $14.5M | 0.85% |
264,278
+30,370
| +13% | +$1.83M |
2024 Q4
5 quarters
|
|
Similar funds
GAMH
RCAG
AWM
TCM
WRBC
IAN
BOI
FM
ADAR1 Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.
- ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
- ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
- ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
- ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
- ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
- ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
- ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.
Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.